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Abstract
As interest in the use of activated recombinant factor VII (rFVIIa) in
trauma grows, questions arise regarding how best to monitor
rFVIIa therapy and when rFVIIa may be expected to improve
hemostasis. Knowledge of the mechanisms of action may be
combined with available data on laboratory monitoring and efficacy
in various coagulopathic states in coming to clinically relevant
conclusions. This review addresses the physiology of hemostasis,
placing emphasis on how rFVIIa influences the process by both
tissue factor dependent and tissue factor independent
mechanisms. This is extended to a mechanistic consideration of
how rFVIIa may function under acidotic, hypothermic, and
hemodilutional and/or consumptive conditions of trauma related
coagulopathy. When these considerations are viewed alongside
the available clinical data, it becomes apparent that rFVIIa has
potential to improve hemostasis during trauma coagulopathy,
within limitations. Common laboratory procedures are discussed
with reference to mechanisms of action of rFVIIa and the available
clinical data. Although there is no single assay that can predict
rFVIIa efficacy in trauma, the prothrombin time (PT) is
recommended as a minimum. Although a shortened PT does not
predict success, correction of PT into the normal range may be a
better indicator. A nonresponding PT appears to indicate that
rFVIIa alone will not lead to hemostasis, and that additional blood
products and other measures must be applied. Once the patient is
more stable, PT and thromboelastography are recommended.
Introduction
In 1983, Hedner and Kisiel [1] reported the successful use of
plasma derived activated factor VII (FVIIa) for the control of
bleeding in two patients with factor VIII (FVIII) antibodies. This
was followed by successful treatment in other patients [2].
However, the procedures required for purification of FVIIa
from plasma precluded extensive use. The shortage was
addressed when NovoNordisk Pharmaceuticals developed a
method to produce recombinant human FVIIa (rFVIIa) using a
transfected baby hamster kidney cell line [3]. The drug
NovoSeven® (Novo Nordisk A/S, Bagsværd, Denmark) is
now registered in many countries worldwide for the treatment
of spontaneous and surgical bleeding in patients with
inhibitors against FVIII or factor IX (FIX) [3]. Over 700,000
standard doses (90 µg/kg) have been administered for
acquired and congenital hemophilia [4]. Recently, there has
been growing interest in the use of rFVIIa to control
hemorrhage in patients without hemophilia. There are
numerous reports of rFVIIa use in patients under a variety of
circumstances, including trauma [5], as reviewed by Grounds
and Bolan in this supplement. As interest in the use of rFVIIa
in trauma grows, questions arise pertaining to how best to
monitor rFVIIa therapy and when rFVIIa may be expected to
work. Regarding the use of rFVIIa in trauma, knowledge of the
mechanism of action may be combined with available data on
laboratory monitoring and efficacy in various coagulopathic
states in coming to clinically relevant conclusions.
Cell based model of hemostasis
Over 40 years ago the cascade model of blood clotting was
introduced [6], a model that was later expanded to include
both the intrinsic and extrinsic (tissue factor [TF]) pathways.
Over the years, observations such as the fact that factor XII
deficiency does not result in a hemorrhagic disease and the
identification of important links between the two pathways
[7,8] pointed to the importance of the TF pathway. By the
1990s it became clear that the TF pathway (extrinsic) of
coagulation was of primary importance in normal hemostasis,
and it became questionable whether the intrinsic pathway
was relevant to in vivo hemostasis [9]. Lawson and
coworkers [10] reported a model of TF initiated coagulation
that described an initiation or lag phase, during which
initiating enzymatic events result in the assembly of highly
efficient enzyme complexes on phospholipid surfaces,
followed by a propagation phase, during which an
exponential burst of thrombin generation occurs. More
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recently, a cell based model has been proposed that differs
from previous models primarily by emphasizing the cellular
control of coagulation in vivo (Fig. 1) [11]. An understanding
of this model is important in understanding the mechanism of
action of rFVIIa. The cell based model includes three
overlapping phases that describe events that take place on
different cell surfaces: initiation, amplification, and
propagation.
Initiation
TF is the primary physiologic initiator of coagulation [9] and is
present in subendothelium and other tissues that are not
normally exposed to blood [12,13]. TF is also expressed on
monocytes following trauma [14] and on endothelium in
response to activation by inflammatory mediators [15]. It may
also be present in plasma [16] and circulating microparticles
under some circumstances [17].
The process begins when vascular damage exposes blood to
subendothelium, which is rich in TF and collagen. Both FVIIa
(which circulates as 1% of total FVII) and FVII bind to TF on
subendothelial cells. The FVIIa/TF complex activates both
factor X (FX) and FIX [10]. TF bound FVII is activated by this
small amount of FXa, producing more TF/FVIIa in a feed
forward manner. FXa also activates plasma factor V (FV) [18],
allowing the formation of the prothrombinase complex
(FXa/FVa/calcium) on the TF bearing cell surface and leading
to the production a small amount of thrombin [10,19].
Amplification
At the site of vascular injury, platelets adhere to the
subendothelium and become partially activated. The small
amount of thrombin produced during initiation fully activates
platelets [20]. This enhances adhesion [21], causes release
of FV from platelet α-granules, and induces a procoagulant
configuration of cell membrane phospholipids and receptors
[19]. On the activated platelet surface, thrombin produced
during the initiation phase activates FV, FVIII, and factor XI
(FXI) [20], which subsequently activates FIX to FIXa. The
result is that the coagulation process has moved to the
activated platelet surface, where the required components of
the tenase complex (FIXa/FVIIIa/calcium) are assembled and
ready to produce FXa, which will allow formation of the
prothrombinase complex on the same surface in preparation
for large scale production of thrombin [19].
Propagation
Small amounts of FIXa produced by the TF/FVIIa on the TF
bearing cell diffuse to the surface of the activated platelet.
This FIXa, along with FIXa produced by FXIa on the platelet,
binds to the platelet surface and combines with FVIIIa,
forming the tenase complex. The tenase complex converts FX
to FXa, which then forms the prothrombinase complex in
combination with FVa. The formation of these complexes
makes possible the highly efficient generation of large
amounts of thrombin from prothrombin [19]. The ‘burst’ of
thrombin results in recruitment of more platelets as well as
the production of fibrin polymers, activation of factor XIII, and
other related events.
Localization of the procoagulant process
The coagulation process is localized to the site of vascular
injury by several mechanisms [19]. The first is localized
exposure of subendothelial elements. FVII and FVIIa have
negligible enzymatic activity in the absence of TF. The binding
of FVIIa to TF provides the enhanced FVIIa activity specifically
where required. Binding and activation of platelets at the
wound site, in close proximity to cells bearing the TF/FVIIa
complex, provides the required procoagulant surface. Other
mechanisms involve three key inhibitors of procoagulant
enzymes and cofactors, antithrombin III, protein C, and tissue
factor pathway inhibitor. FXa and thrombin that diffuse away
from the protected surface of the cell are rapidly inactivated
by antithrombin III [22]. Thrombin binds to thrombomodulin
on adjacent undamaged endothelial surfaces. The
thrombin/thrombomodulin complex activates protein C, which
binds to a specific endothelial receptor and, with its cofactor
protein S, inactivates FVa and FVIIIa, further controlling the
spread of the coagulation process [23]. TF pathway inhibitor
directly inhibits TF/FVIIa [24]. Other interactions among these
enzymes  and inhibitors are also involved. Additionally,
endothelial cells possess a cell surface ADPase, which inhibits
recruitment of platelets to bind to intact endothelium [25].
Mechanisms of action of activated
recombinant factor VII
The normal ratio of FVII to FVIIa in the circulation is 100:1
(10 nmol/l and 0.10 nmol/l, respectively). Following rFVIIa
administration the circulating total FVIIa (rFVIIa and native
Figure 1
A cell-based model of coagulation. The three phases of coagulation
occur on different cell surfaces: initiation on the tissue factor bearing
cell; amplification on the platelet as it becomes activated; and
propagation on the activated platelet surface. vWF, von Willebrand
factor. Reproduced with permission from Hoffman and Monroe [11].S17
FVIIa) concentration is increased approximately 100-fold (to
3–20 nmol/l) such that the FVII:FVIIa ratio is approximately
1:1. It is generally agreed that rFVIIa acts by enhancing
thrombin generation at the site of injury, but there is
controversy over the exact mechanism(s) of action by which
this is accomplished. Current knowledge of the action of
rFVIIa comes primarily from work using systems of simulated
or actual hemophilia conducted to study the ability of rFVIIa to
enhance thrombin production by ‘bypassing’ FVIIIa or FIXa
and the need for the tenase complex. It appears that there are
two principal mechanisms by which rFVIIa acts [26]: a TF
dependent and a TF independent mechanism.
In both mechanisms, rFVIIa augmented coagulation is
initiated at the site of vascular injury by the interaction of
rFVIIa with TF. This results in initial FX activation followed by
thrombin generation. Along with the exposed sub-
endothelium, this initial thrombin acts to recruit and activate
platelets at the site of injury. At this point the mechanisms
diverge.
Under the TF independent mechanism, rFVIIa binds with low
affinity to the surface of activated platelets. This platelet
bound rFVIIa then activates FX to FXa. Although the
enzymatic efficiency of this reaction is low relative to that of
the TF/rFVIIa complex, the pharmacologic concentration of
rFVIIa offsets this inefficiency. Therefore, FXa production
becomes independent of TF with the accumulation of
platelets at the site of injury [19,27]. Under the TF dependent
mechanism, pharmacologic concentrations of rFVIIa result in
an increased proportion of TF occupancy by (total) FVIIa
(either FVIIa or rFVIIa), resulting in a higher concentration of
TF/(r)FVIIa complex at the site of vascular damage [28]. The
rFVIIa must bind to TF to enhance FXa production and
ultimately thrombin generation [29,30]. Under either
mechanism, the remaining steps involve combination of FXa
with FVa on the surface of activated platelets to form the
prothrombinase complex, which converts prothrombin to
thrombin. The mechanisms are not mutually exclusive, and it
is possible that both play a role [26]. Data suggest that the
response in nonhemophilic blood may be slightly different,
involving the additional activity of rFVIIa activating FIX [31].
The localized generation of large amounts of thrombin as a
result of rFVIIa may have the additional beneficial effects of
enhancing platelet adhesion and aggregation [32] and
making formed clots more resistant to fibrinolysis by
increasing activation of thrombin activatable fibrinolysis
inhibitor [33] and/or producing thinner and more tightly
packed fibrin fibers [34].
Activated recombinant factor VII in trauma
coagulopathy
With the rapidly expanding interest in the use rFVIIa in
patients without hemophilia has come debate over whether
rFVIIa may be considered a universal hemostatic agent
[35,36]. Both pro and con arguments in this debate
acknowledge that hemorrhagic situations are not all the
same. Even within the trauma setting a variety of situations
exist, and the risks as well as potential efficacy may vary with
the situation. With respect to the multifactorial coagulopathy
associated with trauma, acidosis, hypothermia, hemodilution,
and/or consumption of factors and platelets are important
factors to consider [37].
Activated recombinant factor VII and acidosis
The coagulopathy associated with acidosis appears to
involve changes in both enzymatic rates [38] and platelet
function [39,40]. In vitro, a reduction in pH from 7.4 to 7.0
reduces TF independent activity of rFVIIa by over 90% and
TF dependent activity by over 60% [38]. Therefore, it is clear
that reduced pH will result in some reduction in efficacy of
rFVIIa. However, considering the fact that rFVIIa
administration increases total circulating FVIIa levels by 100-
fold, it is not clear at what level of acidosis the beneficial
effect of rFVIIa would be nullified. The decrement in the TF
independent mechanism is greater than the effect on the TF
dependent mechanism. To the extent that one mechanism
may be more important than the other in a given situation, the
effects of pH may be variable. In addition to decrements in
enzymatic efficiency, impaired platelet function during
acidosis would also be expected to affect rFVIIa efficacy.
In one report [41] the clinical response to rFVIIa in trauma
patients tended to decline at pH below 7.2 but the effect was
only significant at or below 7.0. Dutton and coworkers [42]
found that mean blood pH was 7.29 in the group of trauma
patients who responded to rFVIIa whereas the pH in the
nonresponders was 7.02 (P < 0.05). However, six out of 20
nonresponders had a pH greater than 7.10, while five
patients with pH at or below 7.10 responded to rFVIIa
therapy. In a case report of a trauma patient who had an
arterial pH of 7.09 at the time of rFVIIa administration [43],
the drug was deemed efficacious. In an early report of
coagulopathic trauma patients [44], rFVIIa was also effective
during acidosis.
Based on currently available information, pH cannot be used
as an absolute guide as to whether rFVIIa therapy will be
effective, but it can be expected that efficacy will be reduced
as pH declines. It is clear that blood pH should be taken into
account when considering use of rFVIIa for management of
trauma coagulopathy, and the recommendation to correct pH
to at least 7.2 before rFVIIa administration is a reasonable
guideline [41].
Activated recombinant factor VII and hypothermia
It is well known that hypothermia decreases the activity of
coagulation enzymes and impairs platelet function such that
blood clotting is slowed. TF dependent activity of rFVIIa
declines by 20% with a drop in temperature from 37°C to
33°C [38]. Interestingly, TF independent activity increases
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under the same experimental conditions [38]. With the
assumption that both the TF dependent and TF independent
activities of rFVIIa play a role, it seems possible that the TF
independent mechanism may make rFVIIa somewhat resistant
to decreases in temperature in terms of hemostatic effect. On
the other hand, rFVIIa cannot be expected to be effective for
all degrees of hypothermia. For the initiation of blood clotting
(initiation phase) at the site of injury, formation of the TF/FVIIa
complex and generation of a small amount of FXa by the TF
dependent mechanism is required. Initiation by this
mechanism would diminish with decreasing temperature. The
other theoretical option is for platelets to adhere to the
subendothelium and become sufficiently activated for rFVIIa
to bind and activate FX by a TF independent mechanism. The
limiting factor in this case could become the lack of platelet
activation under hypothermic conditions [45]. Therefore, it
appears that there will be a level of hypothermia at which
rFVIIa is no longer effective.
rFVIIa appears to be effective at temperatures normally
encountered in trauma, although this has not been fully
studied. Martinowitz and Michaelson [41] reported efficacy in
trauma patients with an average core temperature of 34.1°C.
Similar findings were reported by others [46,47]. In one study
a hemostatic effect at a body temperature as low as 30°C
was reported [44]. Two studies in swine [48,49] also
suggested efficacy in hypothermia, although a third swine
study [50] failed to confirm those findings.
Based on currently available information, rFVIIa can be
expected to be useful for the control of nonsurgical bleeding
under hypothermic conditions encountered in trauma (e.g.
33°C), but loss of TF dependent activity and decreased
platelet function will likely lead to reduced rFVIIa efficacy as
temperature approaches 30°C.
Activated recombinant factor VII and hemodilution/
consumption
Examination of the model of blood coagulation and an
inventory of the normal concentrations of coagulation factors
makes it clear that the process is exquisitely balanced [22].
Changes in the concentrations of various components of the
system can alter greatly thrombin generation and the clotting
process as a whole [51]. Therefore, it is expected that
sufficient dilution or consumption of various components of
the coagulation system will result in coagulopathy. The
potential for efficacy of rFVIIa will be eliminated when
components other than FVIIa become rate limiting. For
example, in the absence of FX or FV, rFVIIa does not shorten
in vitro plasma clotting times [52]. There could also be a
point when fibrinogen [37], prothrombin, or platelets become
rate limiting. This notion is supported by data from 13
patients who were treated with rFVIIa for life threatening
coagulopathy [53]. All patients received blood products
before rFVIIa administration. However, patients who
responded to treatment had a better coagulation status (as
measured by fibrinogen and platelet concentrations, PT, and
activated partial thromboplastin time [aPTT]) at the time of
treatment than did nonresponders.
Nonetheless, rFVIIa does appear to improve hemostasis in
the presence of hemodilution/consumption, within limits. The
trauma cases reported to date have included patients who
received crystalloid and colloidal fluids as well as blood
products in various combinations. It is expected that all of
these patients would have some degree of consumption
and/or hemodilution. There have been a number of reports of
successful use of rFVIIa for patients in consumptive states
(disseminated intravascular coagulation or similar states)
resulting from trauma or other causes [54-60]. In several
cases in which hemodilution was clearly identified, rFVIIa was
effective in controlling bleeding [43,46,60-62]. Two studies
in swine [48,49] also suggest efficacy in hemodilution,
although a third study [50] failed to confirm those findings.
Further studies are needed to elucidate more fully the
combinations of coagulopathic conditions under which rFVIIa
will and will not be effective with regard to trauma. At the
present time, to optimize the opportunity for rFVIIa to enhance
hemostasis, it is recommended that factors and platelets be
replaced to the extent possible before rFVIIa is used
[37,41,57,63]. As a guideline, platelets should be maintained
at a minimum of 50,000/µl and fibrinogen at a minimum of
50 mg/dl. Although the lower limits of pH and temperature
under which rFVIIa may be effective are not clearly defined,
efforts should be made to warm the patient and correct
acidosis before administering rFVIIa treatment [41].
Laboratory monitoring of activated
recombinant factor VII
There is currently no single laboratory test that is satisfactory
for monitoring the clinical efficacy of rFVIIa [41,64,65]. By far
the most commonly used tests have been the PT and the
aPTT, but it has been suggested that the shortening of these
two tests does not necessarily reflect clinical effectiveness
[65]. A variety of other laboratory tests have been used to
monitor or study the effects of rFVIIa under various
conditions. When one is assessing the utility of a laboratory
test in monitoring rFVIIa therapy, it is important to consider
factors such as availability, turnaround time, and relevance of
assay end-points to clinical outcomes, among others [66].
The following is a brief discussion of the potential applicability
of selected laboratory tests in the trauma setting.
Plasma coagulation assays
Prothrombin time
The PT assay measures time to clot formation by the TF
pathway. The assay is performed on a citrated plasma sample
and takes only a few minutes to perform, although logistical
considerations drive local turnaround times. The clotting
reaction is initiated by adding TF and phospholipids (usually
in the form of thromboplastin), and calcium. By the most
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common method, clot formation is detected by the change in
turbidity as the fibrin mesh forms. Because PT specifically
examines the TF pathway, it is sensitive to rFVIIa. Many
studies have demonstrated that rFVIIa shortens PT when
coagulation is normal and in coagulopathy due to trauma and
many other nonhemophilic conditions. The maximal degree of
PT shortening is limited not only by in vivo parameters but
also by the concentration of TF and phospholipids present in
the assay reagents, and by the settings of the instrument.
PT is sensitive to both temperature and pH. Standard PT
assays are run at 37°C and the pH dictated by the reagents
used. Therefore, the correction in PT may not reflect the
actual status of the patient under coagulopathic conditions.
Some automated instruments now perform PT at the patient’s
temperature, which assists in interpretation (perhaps future
advances in instrumentation will account for patient pH).
Simple improvement (shortening) of the PT cannot be used
as a reliable indicator of rFVIIa hemostatic efficacy in trauma.
Both Dutton and coworkers [42] and Eikelboom and
colleagues [67] noted that all patients treated with rFVIIa had
improved PT, even those who did not respond in terms of
hemostasis. There is some indication that the degree of
shortening of PT may correlate with hemostatic efficacy.
Although the PT shortened in all patients following rFVIIa,
Dutton and coworkers [42] found that the post-rFVIIa PT was
shorter in patients who responded hemostatically than in
those who did not. Martinowitz and Michaelson [41] reported
similar findings (Fig. 2). Although currently available data are
limited, it appears that correction of the PT into or below the
normal range may be a better indicator of expected rFVIIa
hemostatic efficacy than a simple numeric reduction in PT.
Although there have been many reports of rFVIIa shortening
PT, we know of only one report in which hemostasis was
attained without a shortening in PT following rFVIIa
administration [68]. Therefore, the PT may be useful in
identifying patients in whom rFVIIa will not be expected to
work. If PT is not shortened after rFVIIa administration, then
replacement of one or more factors in addition to FVIIa may
be indicated.
The PT assay is useful in monitoring rFVIIa treated patients
after a damage control or definitive surgical procedure, or
after re-dosing based on the clinical scenario. The time
course of PT correction follows that of increased plasma FVII
activity after rFVIIa treatment and is dose dependent
[48,49,69-79]. As an alternative to the FVII assay (e.g. if this
is not available), PT may be used to monitor duration of
expected rFVIIa correction of coagulopathy.
In summary, a simple reduction in PT is not useful in
identifying responders to rFVIIa but the lack of a reduction
may identify nonresponders. A reduction in PT into the normal
range may prove to be a better indicator of potential hemo-
static effect. The PT can be useful in monitoring the duration
of expected rFVIIa efficacy. Considering these factors, as well
as the universality of the PT test, it is recommended that PT
be used as a standard laboratory test in trauma patients
receiving rFVIIa.
Activated partial thromboplastin time
This assay measures the time to clot formation by the intrinsic
pathway and is performed using methods similar to the PT.
The difference is that the clotting reaction is initiated by a
source of celite or kaolin, a source of phospholipids
(historically referred to as partial thromboplastin), and
calcium. No TF is added. Often, rFVIIa treatment shortens
aPTT. This phenomenon is due to TF independent activity of
rFVIIa such that rFVIIa generates FXa independently of TF
under the conditions of the assay [52,80]. The aPTT is useful
for monitoring rFVIIa efficacy in clinical hemophilia [81], but
this is not necessarily so in other patients. In some cases
aPTT has been shortened following rFVIIa administration in
trauma patients, whereas in others it has not. Therefore, we
do not consider the aPTT to be a useful assay for making
clinical decisions regarding rFVIIa use in trauma.
Other standard plasma coagulation assays
It is not normally expected that rFVIIa treatment will affect
thrombin time, fibrinogen concentration, or levels of
coagulation factors, with the exception of FVII. However, it
has been observed that administration of rFVIIa may interfere
with results of some factor assays, producing artificially
elevated levels [82]. With the exception of the FVII assay
described below, the standard laboratory coagulation tests
that are based on plasma clot formation (thrombin time,
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Figure 2
Shortening of prothrombin time (PT) values before and after
administration of activated recombinant factor VII (rFVIIa) was significant
in both ‘responders’ (circles: P = 0.0001) and ‘nonresponders’
(triangles; P = 0.016). However, in the latter group the mean PT values
before and after treatment were significantly higher. Reproduced with
permission from Martinowitz and Michaelson [41].S20
fibrinogen, clotting factors) are not useful in monitoring
specifically the effectiveness of rFVIIa in trauma. Although
rFVIIa treatment may interfere with the results of some of
these assays, this phenomenon should not preclude
monitoring of these parameters as necessary to assess
overall patient status, for example to determine the need for
blood products.
The most relevant of the standard factor assays for
monitoring rFVIIa therapy is the FVII assay (factor VII clotting
activity [FVII:C]). This assay does not measure specifically
FVIIa or rFVIIa, but instead it measures total plasma FVII
activity [83]. In a dose dependent manner, rFVIIa increases
FVII activity in a sample far above normal levels [44,48,49,69,
71-73,75-79,82,84-86]. Therefore, the sample must be
diluted by the laboratory in order to calculate an accurate
value. The laboratory should be notified that this is expected.
Although levels are related to the duration of PT correction,
no study has demonstrated that FVII:C levels are predictive of
hemostatic response to rFVIIa in trauma. The value of this
assay in the management of rFVIIa in trauma is limited, but it
can be used to confirm that the dose entered a patient’s
blood stream or to monitor the time course of FVII:C
elevation.
Thrombin generation test
Thrombin generation tests have been used in research but
clinical use has been very limited. In one version, the assay
measures the amount of thrombin generated over time in
platelet poor or platelet rich plasma by monitoring the change
in flourescence as a fluorogenic substrate molecule is
cleaved by thrombin. rFVIIa increases thrombin generation as
detected using this method [87]. Issues related to availability
and complexity currently limit the use of this assay. However,
as automated versions become available, it may become a
useful assay for monitoring rFVIIa therapy in trauma.
Whole blood clotting assays
Thromboelastography
Thromboelastography (TEG) is performed most commonly in
North America using the Thromboelastograph (Haemoscope,
Skokie, IL, USA). In other regions, a slight variation of this
assay is performed using the roTEG Coagulation Analyzer
(PentaPharm, Marburg, Germany). The same general
principals hold for both instruments, although different
nomenclature is used for the various clotting parameters. The
nomenclature for the thromboelastograph is used for the
purpose of this discussion.
TEG monitors changes in the viscoelastic properties of a
forming clot. Either unaltered or citrated blood is delivered
into a sample cup and clotting initiated spontaneously or
using various agonists. A pin is suspended in the blood by a
torsion wire and monitored for motion as the pin is repeatedly
rotated through the blood in a 10 s cycle. Increased blood
viscosity increases resistance to pin rotation and deflects the
pin. The deflection is translated into output measured in
millimeters of amplitude, which increases as blood viscosity
increases. Various standard parameters are calculated,
including reaction time (R), coagulation time (K), α angle,
maximum amplitude (MA), time to reach MA (tMA), and per
cent lysis at 30 or 60 min after MA. R reflects the time to
initial clot formation. K reflects the time from R until a
standardized level of clot firmness is reached (amplitude
20 mm). The α angle is a measure of the kinetics of clot
development. MA reflects the maximum firmness of the clot.
Per cent lysis measurements assess the rate of fibrinolysis.
Recently, two additional TEG parameters – maximum velocity
of clot formation (MaxVel) and time to reach MaxVel (tMaxVel) –
were reported for both versions of the TEG instrument
[77,88]. These parameters appear more sensitive to rFVIIa
than the standard kinetic parameters [88]. It is important to
use dilute TF as the agonist to initiate clotting for best
sensitivity [89,90]. TEG has more traditionally been
performed using agonists that initiate clotting via the intrinsic
pathway, but these agonists yield variable results with rFVIIa
and are not optimal for monitoring this drug.
The most consistent effect of rFVIIa on TF initiated TEG is a
shortening of the R [42,50,77,91-93], but this is not always
observed [49]. Increased MaxVel, α-angle and MA, and
decreased K have also been observed [42,77,90-92].
Hendriks et al. [92] reported no change in rate of fibrinolysis
after rFVIIa treatment. The principal advantage of the TEG is
that it can assess the rate of whole blood clot initiation, rate
of clot development, maximum clot strength, and fibrinolysis
in a single assay. Because it is a whole blood assay it
accounts for the number and function of platelets, as well as
other cellular and plasma phase components. TEG is not a
standard instrument in many hospitals, and the assay normally
takes about 1 hour to perform, even when the instrument is
located in the operating room. However, it can be performed
much more rapidly if one is interested only in R. These
drawbacks notwithstanding, TEG using dilute TF to initiate
clotting can be a useful and sensitive method to monitor
rFVIIa therapy.
Other whole blood clotting assays
The activated clotting time (ACT) assay measures the time
required for clot formation using whole blood, usually with
clotting initiated via the intrinsic pathway. Although the ACT
is commonly available, reports of use of the ACT after rFVIIa
treatment are limited. One study reported a faster clot time in
blood from pigs treated with rFVIIa [77]. Recently available
modified ACT assays that use a TF reagent to initiate clotting
may prove useful in monitoring rFVIIa treated patients. The
platelet function analyzer (PFA) assesses primarily the ability
of platelets to form a hemostatic plug and has been related to
bleeding time [94]. In one study [95] PFA values before and
after rFVIIa treatment was not related to efficacy in patients
with platelet defects. Current data do not support the use of
PFA as a standard parameter in monitoring rFVIIa therapy in
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trauma. The Hemodyne hemostasis analyzer (Hemodyne Inc.,
Richmond, VA, USA) monitors platelet contractile force over
time and clot elasticity. Thrombin generation time can also be
determined [96]. Although this assay offers some advantages
over other whole blood assays and appears useful for rFVIIa
monitoring, it is not widely available.
Recommendations for monitoring and interpretation of
laboratory values
Recently, several articles have examined the issue of rFVIIa
monitoring [66,81,89,96]. Although numerous methods are
available, the issue remains that there is no currently available
single laboratory monitor that predicts rFVIIa efficacy
[41,64,65]. There are factors related to trauma that make
monitoring more problematic than for other patients. The
most important of these is the issue of turnaround time. The
rapidly changing status of the patient during the use of
multiple blood products, colloids, and crystalloids during
active resuscitation and ongoing hemorrhage is another
factor, as is the uncertain half-life of a given dose of rFVIIa
under these conditions. When a trauma patient has
uncontrollable coagulopathic bleeding, it is usually not
possible to wait for laboratory results before taking further
action. Instead, empiric treatment with rFVIIa and direct
observation must be used. Nonetheless, comparison of
laboratory values after treatment with those before treatment
can provide valuable information. Especially in cases in which
continued bleeding may be obscured by packing, when
intracranial hemorrhage is the target for hemostasis, or when
rFVIIa treatment is administered under relatively more controlled
circumstances, laboratory monitoring can be very useful.
The use of the PT is recommended. Although a simple
shortening of PT does not predict hemostatic efficacy,
correction of PT into the normal range may be a better
indicator. It appears that a nonresponding PT indicates that
rFVIIa alone will not lead to hemostasis, and that additional
blood products and other measures must be applied. Once
the patient is more stable, PT and TEG are recommended.
FVII:C may also be useful in some situations. Other laboratory
measurements, although useful for answering specific
questions and monitoring overall patient status, are not
necessary for basic rFVIIa monitoring in trauma.
Conclusion
Whether by a TF dependent or TF independent mechanism,
or by a combination, it is agreed that the hemostatic efficacy
of rFVIIa is due to its ability to increase thrombin generation in
a localized manner at the site of vascular injury. Thrombin
generation is dependent on the assembly and activity of key
enzyme complexes on the membranes of activated platelets.
Mechanistic considerations and available clinical reports are
consistent with the concept that rFVIIa administration can
improve hemostasis under conditions of acidosis, hypo-
thermia, and hemodilution/consumption, within limits.
Because of the effects of acidosis and hypothermia on
enzymatic rates and platelet function, it is expected that
extremes of acidosis and hypothermia will be reached at
which rFVIIa can no longer be expected to function. Evidence
for efficacy at least to a pH in the region of 7.2 and to a core
temperature of 34°C is growing, although it is likely that the
limits of efficacy are somewhat lower. When hemodilution/
consumption reaches a point at which a component other
than FVIIa becomes rate limiting, rFVIIa efficacy will be
impossible without replacement of other components, such
as FV, FX, prothrombin, fibrinogen, and platelets. Current
recommendations to give blood products and to attempt to
correct acidosis and hypothermia before rFVIIa administration
are consistent with the current understanding of rFVIIa
mechanisms of action [37,41,63] but further research is
needed to define more clearly the limitations of rFVIIa efficacy
under the multifactorial coagulopathic conditions associated
with trauma.
During active resuscitation and damage control procedures,
laboratory monitoring may be too slow to permit its
meaningful use in clinical decision making. There is currently
no replacement for direct observation of hemostatic effect.
Comparison of laboratory values after treatment with those
before treatment can provide valuable information. Especially
when continued bleeding may be obscured by packing, when
intracranial hemorrhage is the target for hemostasis, or when
rFVIIa treatment is administered under relatively more
controlled circumstances, laboratory monitoring is essential.
Although no laboratory test can predict the hemostatic
efficacy of rFVIIa, the use of the PT is recommended. A
shortened PT does not predict success, but correction of PT
into the normal range may be a better indicator. A
nonresponding PT appears to indicate that rFVIIa alone will
not lead to hemostasis, and that additional blood products
and other measures must be applied.  Once the patient is
more stable, PT and TEG are recommended. FVII:C may also
be useful in some situations.
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